HIV vaccine vCP1521

Drug Profile

HIV vaccine vCP1521

Alternative Names: ALVAC-HIV-vCP1521; Aventis Pasteur live recombinant ALVAC-HIV (vCP1521) priming vaccine + VaxGen gp120 B/E (AIDSVAX B/E) boosting vaccine; vCP1521

Latest Information Update: 09 Jun 2015

Price : $50

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi Pasteur
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III HIV-1 infections

Most Recent Events

  • 09 Jun 2015 HIV vaccine vCP1521 is still in phase II trials for HIV-infections (Prevention, In volunteers) in Thailand
  • 08 Apr 2014 Sanofi pasteur and the National Institutes of Health complete enrolment in a phase Ib trial for HIV-infections (prevention, in volunteers) in South Africa before April 2014 (NCT02109354)
  • 30 Jun 2013 Phase-I clinical trials in HIV-1 infections (prevention, in volunteers) in South Africa (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top